B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083140" target="_blank" >RIV/00216224:14110/15:00083140 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00063247

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2015/792187" target="_blank" >http://dx.doi.org/10.1155/2015/792187</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2015/792187" target="_blank" >10.1155/2015/792187</a>

Jazyk výsledku

angličtina

Název v původním jazyce

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Popis výsledku v původním jazyce

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia.

Název v anglickém jazyce

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Popis výsledku anglicky

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EI - Biotechnologie a bionika

OECD FORD obor

—

Projekt

<a href="/cs/project/LM2011017" target="_blank" >LM2011017: Advanced Cell Immunotherapy Unit - ACIU</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomed Research International

ISSN

2314-6133

e-ISSN

—

Svazek periodika

2015

Číslo periodika v rámci svazku

"792187"

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

1-9

Kód UT WoS článku

000359550200001

EID výsledku v databázi Scopus

—